• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden. *

 

	Start	0199-01-01 established
	Industry	cancer drug
	Industry 2	DRUGS, VETERINARY
	Person	Martelet, Francois R. (Oasmia 202008 CEO before TopoTarget 201011 CEO)
	Person 2	af Winklerfelt, Michael (Oasmia 202008 CFO)
	Region	Uppsala
	Country	Sweden
	Street	1 Vallongatan
	City	725 28 Uppsala
	Tel	+46-18-505440
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for �About Section�:
		Record changed: 2020-09-08

Advertisement

More documents for Oasmia Pharmaceutical AB

• [1] Oasmia Pharmaceutical AB. (9/8/20). "Press Release: Oasmia Pharmaceutical Appoints Fredrik Järrsten as Chief Financial Officer". Uppsala....
• [2] Oasmia Pharmaceutical AB. (8/10/20). "Press Release: Oasmia Pharmaceutical Appoints Peter Selin as Chief Business Officer". Uppsala....
• [3] Oasmia Pharmaceutical AB. (11/30/17). "Press Release: Oasmia Has Completed a Private Placement of New Convertible instruments in a Total Amount of SEK 28,000,000"....
• [4] Oasmia Pharmaceutical AB. (3/3/17). "Press Release: Interim Report for the Period May 2016 – January 2017. Strategic Changes within Animal Health Division". Uppsala....
• [5] Oasmia Pharmaceutical AB. (3/1/17). "Press Release: Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors". Uppsa...
• [6] Oasmia Pharmaceutical AB. (2/28/17). "Press Release: Oasmia Pharmaceuticals Chairman Anders Lönner Resigns". Uppsala....
• [7] Oasmia Pharmaceutical AB. (1/23/17). "Press Release: Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division". Uppsala....
• [8] Oasmia Pharmaceutical AB. (12/21/16). "Press Release: Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea (Paclical)". Uppsala....
• [9] Oasmia Pharmaceutical AB. (10/24/16). "Press Release: Oasmia Successfully Completes Private Placement of SEK 70 Million". Uppsala....
• [10] Oasmia Pharmaceutical AB. (10/24/16). "Press Release: Oasmia Enters into Collaboration Agreement for Novel Cancer Project". Uppsala....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.